Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy
Explore this paper's citation graph
Summary
It is confirmed that POA bound to RpsA (but not a clinically identified ΔAla mutant) and subsequently inhibited trans-translation rather than canonical translation, and its inhibition may explain the ability of PZA to eradicate persisting organisms.
- Type
- article
- Published
- 2011-08-11
- Cited by
- 515
- References
- 40
- Access
- Open access
- OpenAlex
- https://openalex.org/W1975610050
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12065122
Keywords
Pyrazinamide, Mycobacterium tuberculosis, Tuberculosis, Translation (biology), Bacteria
References
- Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
- The curious characteristics of pyrazinamide: a review.
- Current Development and Future Prospects in Chemotherapy of Tuberculosis
- Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
- Levels of ribosomal protein S1 and elongation factor G in the growth cycle of Escherichia coli
- Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
- An easy cell-free protein synthesis system dependent on the addition of crude Escherichia coli tRNA.
- Simultaneous and functional binding of SmpB and EF-Tu-TP to the alanyl acceptor arm of tmRNA.
- The solution structure of the S1 RNA binding domain: a member of an ancient nucleic acid-binding fold.
- The action of antituberculosis drugs in short-course chemotherapy.
- SsrA genes of streptomycetes and association of proteins to the tmRNA during development and cellular differentiation
- Mechanisms of drug resistance in Mycobacterium tuberculosis.
- Protein tagging at rare codons is caused by tmRNA action at the 3' end of nonstop mRNA generated in response to ribosome stalling.
- Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
- The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
- Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus
- Crystal structure of the Xrcc4 DNA repair protein and implications for end joining
- Trans-Translation in Helicobacter pylori: Essentiality of Ribosome Rescue and Requirement of Protein Tagging for Stress Resistance and Competence
- Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis
- Emerging drugs for the treatment of tuberculosis
Cited by
- Fluorescence Characterization of the tRNA-like Domain of tmRNA in Complex with SmpB
- Molecular and biochemical characterisation of mycobacterial cell wall drug targets - Lipoarabinomannan
- Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.
- Drug development against tuberculosis: Past, present and future.
- Synthesis and evaluation of transvalencin analogues and adenylation inhibitors as antitubercular agents and chemical probes
- Studies into the role of peptidoglycan glycolylation in mycobacterial dormancy and resuscitation
- Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.
- Role of the two ClpP protease subunits in Mycobacterium tuberculosis
- Advances in Drug Discovery and Development for Pediatric Tuberculosis
- The chemotherapy of tuberculosis: past, present and future
- Molecular Biology of Drug Resistance in Mycobacterium tuberculosis
- Evaluation of Different Mycobacterial Species for Drug Discovery and Characterisation of Novel Inhibitors of Mycobacterium Tuberculosis
- Investigating the mode of action of tuberculosis drugs using hypersensitive mutants of Mycobacterium smegmatis
- Current status and research strategies in tuberculosis drug development.
- Induced ectopic expression of HigB toxin in Mycobacterium tuberculosis results in growth inhibition, reduced abundance of a subset of mRNAs and cleavage of tmRNA
- Advances in the treatment of pulmonary tuberculosis.
- A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis
- Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis
- Gene expression profiling reveals potential key pathways involved in pyrazinamide‐mediated hepatotoxicity in Wistar rats
- Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations.
Related papers
- Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance
- Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature
- Mutations Associated with Pyrazinamide Resistance in the Clinical Isolates of Mycobacterium tuberculosis
- Rapid Detection of Pnca Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Clinical isolates
- A simplified pyrazinamidase test for pyrazinamide drug susceptibility in Mycobacterium tuberculosis.
- Impact of the host environment on the antitubercular action of pyrazinamide
- Clinically prevalent mutations in Mycobacterium tuberculosis alter propionate metabolism and mediate multidrug tolerance
- Antibiotic resistance in Mycobacterium tuberculosis alters tolerance to cell wall-targeting inhibitors
- Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing.